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Abstract
Serum amyloid A (SAA) is an acute phase protein involved in the homeostasis of inflammatory responses and appears to be
a vital host defense component with protective anti-infective properties. SAA expression remains poorly defined in many
tissues, including the urinary tract which often faces bacterial challenge. Urinary tract infections (UTIs) are usually caused by
strains of uropathogenic Escherichia coli (UPEC) and frequently occur among otherwise healthy individuals, many of whom
experience bouts of recurrent and relapsing infections despite the use of antibiotics. To date, whether SAA is present in the
infected urothelium and whether or not the induction of SAA can protect the host against UPEC is unclear. Here we show,
using mouse models coupled with immunofluorescence microscopy and quantitative RT-PCR, that delivery of UPEC either
directly into the urinary tract via catheterization or systemically via intraperitoneal injection triggers the expression of SAA.
As measured by ELISA, serum levels of SAA1/2 were also transiently elevated in response to UTI, but circulating SAA3 levels
were only up-regulated substantially following intraperitoneal inoculation of UPEC. In in vitro assays, physiological relevant
levels of SAA1/2 did not affect the growth or viability of UPEC, but were able to block biofilm formation by the
uropathogens. We suggest that SAA functions as a critical host defense against UTIs, preventing the formation of biofilms
both upon and within the urothelium and possibly providing clinicians with a sensitive serological marker for UTI.
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Introduction
Upon entering the urinary tract, strains of uropathogenic
Escherichia coli (UPEC) face a barage of both constitutive and
inducible host defenses. Despite this hostile environment, which
often includes the presence of antibiotics, UPEC is frequently able
to establish itself within the host, multiply, and persist for many
days to months. Persistence of UPEC within the bladder is in part
attributable to the ability of these pathogens to invade urothelial
cells where they can either multiply, forming large biofilm-like
communities, or alternatively establish latent resevoirs which may
ultimately lead to episodes of recurrent or relapsing urinary tract
infections (UTIs) [1,2]. Persistent and recurring UTIs due to
UPEC represent a major clinical and financial burden worldwide
[1]. The development of better approaches for the prevention and
treatment of UTIs is dependent upon improved understanding of
UPEC virulence strategies as well as the make-up and limitations
of the host defenses employed against UPEC.
Serum amyloid A (SAA) is an acute phase protein thought to be
involved in inflammation and homeostasis. SAA is a seemingly
critical host defense component and has been reported to have
beneficial properties in the protection against fungal, viral, and
bacterial infections [3,4,5,6,7,8,9], and may help reduce the
incidence of recurrent infections [4]. In planar lipid bilayers, SAA
can assemble into hexameric structures, each containing a central
channel of about 2.5 nm in diameter, and having the potential to
damage bacterial membranes [10,11]. Overexpression of SAA by
intestinal epithelial cells in culture can reduce E. coli viability [12],
and in in vitro assays SAA can act as an opsonin for various Gram-
negative bacteria by binding to the highly expressed outer
membrane protein OmpA [9]. Of note, the ability of some E.
coli strains to invade host cells and form biofilms is critically
dependent upon OmpA [13,14,15,16]. Preferential binding of
SAA to OmpA over endogenous host ligands, including high
density lipoprotein (HDL) [4], may significantly impact both the
host environment and pathogen fitness during the course of an
infection.
During acute phase responses to infection, SAA secretion by
hepatocytes can be greatly increased, leading to highly elevated
concentrations of SAA in the circulation. This phenomenon is
common among vertebrate species. For example, LPS treatment
stimulates SAA expression by salmon hepatocytes [17] and in
zebrafish infection models, SAA is often among the most highly
upregulated gene products [18,19,20,21]. In reindeer, as well as
mice and humans, SAA can be used as a sensitive marker of the
acute phase response to bacterial infection [22]. Similarities in
SAA as an acute-phase marker in both mice and humans make
mice an accessible model for investigating the regulatory and
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classical human inflammatory marker C-reactive protein (CRP),
which is not expressed in mice. It was recently reported, based on
measurements from 219 blood donors, that SAA concentrations in
sera have a median value of 20 mg/ml as determined by ELISA
[23]. SAA is induced in murine models of both E. coli-associated
mastitis [24] and colitis [12,25], but there is currently no data
regarding changes in localized or systemic levels of SAA during a
UTI.
Four functional isoforms of SAA are present in mice [26]. SAA1
and SAA2 are highly homologous isotypes produced primarily in
the liver. SAA3 is evolutionarily distinct from SAA1/2 and can be
synthesized extrahepatically, with abundant expression found in
adipose tissue and the mouse colon [12,25]. SAA3 has also been
identified as the most up-regulated message following E. coli
infection of primary mammary epithelial cells [27]. In addition, in
vitro experiments showed that a 10-mer peptide derived from
human mammary-associated serum amyloid A3 (M-SAA3) can
interfere with the adherence of enteropathogenic E. coli (EPEC) to
intestinal epithelial cells [28]. Results presented here demonstrate
that SAA1/2, and to a lesser extent SAA3, are induced both
locally within the bladder and systemically in response to infection
with UPEC. Furthermore, we show that UPEC is resistant to any
bactericidal or bacteriostatic effects associated with SAA, although
this acute phase protein can effectively inhibit biofilm formation by
the uropathogens.
Materials and Methods
Ethics Statement
Mice were used for this study in accordance with European
guidelines and the Slovenian legislation. The study was approved
by the Veterinary Board of Slovenia Ethics Committee with the
permit number 34401-8/2009/6.
Animals and bacterial strains
Adult 8-week-old female C57BL/6JOLaHsd mice were housed
at room temperature (22–24uC) with 45–65% humidity and a 12-
hr light/12-hr dark cycle and received food and water ad libitum.
Animals were euthanized by CO2 inhalation. The K-12 strain
MG1655 and the UPEC isolates UTI89 and F11 have been
described previously [29,30,31].
SAA
Lyophilized human recombinant serum amyloid A (SAA,
endotoxin-tested) (Peprotech, London, UK) was spun down,
reconstituted according to manufacturer’s instructions in cell
culture grade sterile water to a stock concentration of 1 mg/ml, and
stored at 220uC until used. This recombinant SAA is a hybrid
between SAA1 and SAA2, being identical to human SAA1a
except for the presence of an N-terminal methionine and SAA2b-
like substitutions of asparagine to aspartic acid and arginine to
histidine at positions 60 and 71, respectively.
Mouse UTI model
Mice were anesthetized with ketamine HCl (100 mg/kg i.p.)
and xylazine (10 mg/kg i.p.) prior to inoculation with a 100 ml
suspension of UTI89 (10
8 CFU) in phosphate-buffered saline
(PBS) via transurethral catheterization using a sterile polyethylene
catheter with 0.28 mm inside diameter (Intramedic, Becton
Dickinson, Sparks, MD, USA). Before catheterization, the bladder
of each animal was emptied by gentle pressure on the abdomen.
Infusions were performed gradually and at a slow rate to avoid
injury or vesicoureteral reflux. The catheter, sheathed over a 30 G
needle connected to a 1 ml syringe, was retained in the urinary
bladder for 30 min. After removal of the catheter, mice were
allowed to void normally. To check if this infection protocol
resulted in pyelonephritis, we tested the kidneys of infected mice.
Paraffin sections of kidneys, which were recovered 24 h, 4 days
Figure 1. Induction and localization of SAA1/2 following inoculation of the bladder with UPEC. Immunofluorescence miscroscopy of
bladder sections showing SAA1/2 (red) levels and distribution in sham-infected (PBS-treated) mice (A) and mice that were infected for either one (B)
or four days (C) via intravesical instillation of the UPEC isolate UTI89. (D and E) Localization of UPEC (green) with host cell nuclei (blue) and SAA1/2 at
4 d post - inoculation of the bladder with UTI89. Large arrows point to the apical membrane of urothelium and bars mark the border between
urothelium and lamina propria. Small arrows indicate a few bacteria that do not co-localize with SAA1/2.
doi:10.1371/journal.pone.0032933.g001
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pathologist, provided no evidence of bacterial infection or
inflammation. Urinary bladders, liver and blood were taken
immediately after sacrifice.
Intraperitoneal infections
Four mice were inoculated via intraperitoneal injection with
200 ml of a suspension containing 10
8 CFU of UTI89 in PBS. The
same amount of sterile PBS was received by four sham inoculated
animals. After 1 day, mice were sacrificed and bladders, liver and
blood were taken immediately.
Immunofluorescence labeling
Bladders were fixed for 2 h using 3% paraformaldehyde in PBS,
rinsed overnight in 30% saharose, frozen, and cut into 7-mm-thick
sections. After washing in PBS, sections were permeabilized in
cold acetone for 5 min, quick-dried, blocked in 3% BSA in PBS
and incubated overnight at 4uC with primary antibodies against
SAA (rabbit polyclonal antibodies developed against synthetically
produced peptides of SAA1/2; a gift of Prof. Malle, Medical
University of Graz) diluted 1:100 in 1% BSA in PBS. After
washing in PBS, samples were incubated in the dark at 37uC for
1 h with Alexa FluorH 555 labelled goat anti-rabbit secondary
antibodies (Invitrogen, Molecular Probes, Leiden, Netherlands)
diluted 1:300 in 1% BSA in PBS. After prolonged washing in PBS,
sections were incubated at 37uC for 1 h with fluorescein
isothiocyanate (FITC)-labelled rabbit polyclonal antibodies against
E. coli (1:10; Abcam, Cambridge, UK). After additional washing in
PBS, sections were mounted in antibleaching mounting medium
Vectashield containing 49, 6-diamidino-2-phenylindole (DAPI)
(Vector Laboratories, Burlingame, CA, USA) to stain DNA.
Proper negative controls, in which both primary antibodies were
replaced with serum from non-immunized animals, were per-
formed. The samples were analysed using a Nikon Eclipse TE 300
fluorescence microscope (Amstelveen, Netherlands).
ELISA
Mouse serum was centrifuged from whole blood collected using a
syringe in the heart, aliquoted, and stored at 220uC until used. The
concentrations of SAA1 (Invitrogen, CA, USA) and SAA3
(Millipore, MA, USA) were measured in duplicate assays following
the manufacturer’s instructions. Samples were thawed, allowed to
reach room temperature and, if necessary, diluted with standard
diluent buffer (1:40 for SAA1, undiluted for SAA3, except in
samples from IP injected mice, where an 1:2000 was used) provided
in the ELISA kits. After obtaining absorbance readings, SAA
concentrations were calculated from standard curves. Statistical
analysis was performed using mean 6 SD and Student’s t-tests.
RNA isolation and quantitative PCR analysis
Total RNA from various mouse tissues, including the liver,
urothelium (mechanically peeled away from the bladder), and
urinary bladder wall without the urothelium, was isolated using
PureLink RNA Mini Kit (Invitrogen, CA, USA) following the
manufacturer’s instructions. The purity and amount of RNA was
determined by measuring the OD at a ratio of 260 to 280 nm.
cDNA was generated from 1 mg of total RNA using the Reverse
Transcription System (Promega, WI, USA) with oligo(dT) primers,
and qPCR was performed with StepOne (Applied Biosystems, CA,
Figure 2. Quantification of SAA mRNA expression in response
to UPEC. Four mice were either sham inoculated with PBS alone or
infected with UTI89 via catheterization to initiate UTI. Alternatively,
mice were infected systemically via IP injections of UTI89, with control
animals recieving only PBS. After 1 d, levels of SAA1/2 and SAA3 in the
(A) bladder wall, (B) isolated urothelium, and (C) liver were quantified
relative to ribosomal L32 transcript levels. *, p,0.05 relative to sham
inoculated animals as determined by Student’s t test. The mean +/2 SD
of triplicate experiments are shown.
doi:10.1371/journal.pone.0032933.g002
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Biosystems, Warrington, UK) using SAA-specific primers and
ribosomal protein L32 primers serving as endogenous control for
normalization as described in [25]. Dissociation curves of products
showed only one peak in each PCR reaction. 900 nM of forward
and reverse primers were used to amplify SAA1/2 and SAA3,
while 300 nM of primers were used for L32. Data analysis was
done using 2DDCt method with normalization to the level of L32.
Biofilm and Bacterial Growth Assays
Microtiter plate-based biofilm assays were carried out as
previously described [2]. In brief, bacterial strains from overnight
shaking cultures were diluted 1:100 in M9 minimal medium, and
quadruplicate 100-ml samples were incubated 60, 0.5, 1 and
5 mg/ml SAA in 96-well pinchbar flat-bottomed polystyrene
microtiter plates with lids for two days at 30uC without shaking.
Nonadherent bacterial cells were then removed by gentle washings
with distilled H2O and the remaining biofilm-associated bacteria
were stained for 10 min at room temperature with 150 mlo fa
0.1% solution of crystal violet in water, (Sigma-Aldrich, MO,
USA). Wells were then washed with H2O, air dried for 30 min,
and incubated for 15 min with 200 ml dimethyl sulfoxide (DMSO)
to release the incorporated dye. After transferring a 150-ml aliquot
from each well to a new microtiter plate, A562 was measured using
a Synergy HT multidetection plate reader (BioTek Instruments,
Inc., VT, USA).
Bacterial growth curves were acquired using quadruplicate 200-
ml cultures of MG1655, UTI89, and F11 shaking in M9 minimal
medium 60, 5, or 20 mg/ml SAA at 37uC in 100-well honeycomb
plates using a Bioscreen C instrument (Growth Curves, USA), as
previosuly described [32].
Results
To investigate the ability of UPEC to affect SAA expression in
the host, we employed a well-established mouse UTI model
system. At 1 and 4 d following catheterization of adult female
C57BL/6JOLaHsd mice with the UPEC isolate UTI89, levels of
SAA1/2 in the urothelium were observed to be notably elevated
relative to uninfected controls (Fig. 1A–C). Within the urothelial
cells, SAA1/2 was primarily situated within the cytosol, where it
co-localized strongly with internalized UPEC (Fig. 1D and E).
Upregulation of SAA at day 1 post-inoculation of the bladder with
UTI89 was confirmed by qRT-PCR of the bladder wall as well as
the isolated urothelium and the liver (Fig. 2). SAA1/2 expression
levels were elevated more than 4.8-fold in the liver and
urothelium, and more than 30-fold in the bladder wall, while
the relative induction of SAA3 expression in these tissues in
response to UTI was less robust. However, in control experiments
in which mice were infected systemically with UTI89 delivered via
intraperitoneal (IP) injection, SAA3 expression was markedly
increased in the liver (more than 300-fold) as well as in the
urothelium (,20-fold) and bladder wall (,90-fold).
Within 1 d following instillation of mouse bladders with UTI89,
we observed by ELISA a substantial 8-fold increase in SAA1
serum levels, which decreased by day 4 and remained subdued up
to day 14 (Fig. 3A). In contrast, serum levels of SAA3 were not
altered in response to UTI (data not shown). However, following
IP injection of UTI89 we did detect significant and notably large
increases in circulating SAA3 levels along with corresponding,
although smaller, increases in SAA1/2 levels (Fig. 3B). This is the
first time, to our knowledge, that serum SAA3 protein levels have
been shown to increase substantially in response to UPEC
delivered intraperitoneally.
Previous work indicated that recombinant SAA1/2 expressed
by cultured host cell lines can inhibit the growth and viability of
laboratory E. coli K-12 strains [12], raising the possibility that SAA
may act similarly against UPEC isolates during the course of a
UTI. However, in in vitro assays, we found that growth of the
UPEC isolates UTI89 and F11 in M9 medium was unfazed by
SAA concentrations up to 100 mg/ml (data not shown and Fig. 4),
indicating that SAA does not have direct bactericidal or
bacteriostatic effects on UPEC. Interestingly, SAA also had no
effect on growth of the reference K-12 isolate MG1655 in our
assays. In considering alternate means by which SAA could
potentially affect the pathogenesis of UTIs, we noted previous
reports indicating that SAA can opsonize Gram-negative bacteria
by binding the abundant outer membrane protein OmpA [4,9].
OmpA is an important facilitator of biofilm formation by UPEC
and other E. coli isolates (unpublished observations and [15]), and
biofilm formation both on and within the urothelium is thought to
promote the establishment and persistence of UPEC within the
urinary tract [1,30]. To test possible effects of SAA on biofilm
formation by UPEC, we employed standard in vitro microtiter plate
Figure 3. ELISA of mouse sera at different time points after infection. Four mice were inoculated with UTI89 via either (A) transurethral
catheterization or (B) IP injection. (A) Serum levels of SAA1/2 and SAA3 in mice were quantified by ELISA in sham inoculated animals and at 1, 4, and
14 d after UTI89 instillation into the bladder (UTI). SAA3 was not detected in these samples. (B) Substantially higher serum levels of SAA1/2 and SAA3
were detected 1 d after infection with UTI89 via IP injection. *, p,0.05 relative to sham inoculated animals as determined by Student’s t test. The
mean +/2 SD of triplicate experiments are shown.
doi:10.1371/journal.pone.0032933.g003
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concentration of SAA (5 ug/ml) significantly inhibited biofilm
formation by UTI89 as well as F11 (Fig. 5).
Discussion
A few decades ago the first publication emerged indicating that
SAA and CRP act as the most reliable markers for monitoring
antimicrobial therapy in patients with UTIs [33]. SAA and CRP
levels were also found to be higher in bacterial infections than in
viral infections, although SAA appeared to be more clinically
relevant as a marker of inflammation in acute viral infections [34].
Initial reports on the anti-microbial activities of SAA were
published about a decade ago with work showing that recombi-
nant SAA can enhance the anti-fungal activities of polymorpho-
nuclear cells (PMNs) [35]. Within 30 min of stimulation, SAA was
found to promote the upregulation of cytosolic Ca
++ concentra-
tions, cell-surface expression of CD11c and CD16 (antigens
involved in adhesion and microbial recognition), and elevation of
lactoferrin secretion. Lactoferrin itself is an anti-microbial agent,
which enchances PMN phagocytic activity against heat-killed yeast
Candida albicans.
More recently, SAA was shown to interact with hepatitis C
(HCV) virions, thereby blocking viral entry [6]. Although no
clinical correlation in this study could be found between sera levels
of SAA and HCV viral loads, a tight relationship between SAA
and HDL levels in modulating HCV infectivity has been proposed
[3,5]. SAA has also been shown to inhibit HIV-1 infection of host
cells via CCR5 receptors [5,7]. SAA appears to be one of the
earliest systemic anti-viral responses to HIV-1, being induced as
early as 5–7 days prior to the first detection of plasma viral RNA
and considerably earlier than other systemic cytokines. Such
observations indicate that SAA can act as a front line anti-viral
defense prior to systemic activation of other immune responses [5].
SAA also appears to play a major role as host defense against
bacterial pathogens, acting as an opsonin able to rapidly bind with
high affinity to many Gram-negative bacteria, including E. coli,
Pseudomonas aeruginosa, Salmonella typhimurium, Shigella flexneri, Klebsi-
ella pneumoniae, and Vibrio cholerae [4]. Binding of SAA to E. coli was
found to be mediated primarily through interactions with OmpA,
as OmpA deficient E. coli did not to bind SAA [9]. Importantly,
the concentration of SAA required for half-maximal binding to E.
coli is within physiologically relevant levels and does not require
other acute phase responses [4]. In vitro, neutrophils phagocytose
K-12 E. coli more readily and in higher numbers following
opsonization of the bacteria with physiologically normal levels of
SAA [9]. More recently, overexpression of SAA1/2 by epithelial
cells has been shown to reduce the viability of a co-culured K-12
E. coli strain via an as-yet undefined mechanism [12]. In contrast
to these antimicrobial effects, SAA may in some cases be
detrimental to the host. For example, SAA has been shown to
Figure 4. Growth of UTI89, F11, and MG1655 ± SAA. Bacterial
growth in M9 medium with 0, 5, or 20 mg/ml SAA was determined by
measuring OD600 over time. Each curve represents the means of results
from quadruplicate samples.
doi:10.1371/journal.pone.0032933.g004
Figure 5. Biofilm formation by the UPEC isolates UTI89 and F11
± SAA. Biofilm levels were quantified by measuring A562 after 48 h
static growth in M9 medium 60, 0.5, 1 and 5 mg/ml SAA. *, p,0.001, as
determined by Student’s t test. Results show the mean values 6 SEM of
three independent experiments performed in quadruplicate.
doi:10.1371/journal.pone.0032933.g005
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Pneumonia (a Gram-negative pathogen that is often resistant to
many antibiotics), and may thereby actually facilitate, rather than
inhibit, bacterial survival and outgrowth [8].
Here we report for the first time that SAA (specifically SAA1/2
and to a smaller extent SAA3) is greatly induced in the bladder
wall and, to a lesser extent, the urothelium in response to UPEC
instilled into the urinary tract via catheterization. As seen by
immunofluorescence microscopy, infection with UPEC resulted in
high levels of cytoplasmic SAA in comparison to the more
subdued, primarily nuclear expression pattern of SAA in
uninfected urothelial cells (see Fig. 1). Heightened levels of SAA
expression within the bladder wall versus the urothelium suggest
that infiltrating immune effector cells and resident host cells within
this compartment are primary contributors to SAA production
during a UTI. Enhanced levels of SAA1 expression in response to
UPEC within the urinary tract were also observed systemically,
being detected in the liver and transiently within the serum of
infected mice. Direct inoculation of UPEC into the peritoneum
also increased levels of SAA1 and SAA3 within both the liver and
general circulation, with only SAA3 increased in the bladder wall
and urothelium.
Although the physiological role of SAA during a UTI remains
to be tested in vivo, the robust localized and systemic amplification
of SAA in response to infection with UPEC suggests a critical role
for this acute phase protein as a host defense against UTIs. UPEC
isolates are often more resistant to environmental stresses and host
defense mechanisms [36], and this phenomenon appears to also be
true in the case of SAA. While SAA expressed by cultured host
cells can interfere with the viability of laboratory E. coli K-12
strains [12], we found that growth of UPEC as well as the K-12
strain MG1655 proceeds unhindered even in the presence of high
levels of SAA. It may be that the previously reported bacteridal
effects of SAA require additional co-factors not present in our in
vitro assays. However, we did find that SAA can potently inhibit the
ability of UPEC isolates to form biofilms, possibly by binding to
and occluding OmpA. The formation of both extra- and
intracellular biofilm communities by UPEC can impact the
establishment and persistence of these microbes within the urinary
tract [13,32,37]. By interfering with biofilm development, SAA
may increase the susceptibility of UPEC to other host defense
mechanisms while also depriving the pathogens of a strong
foothold within the urothelium in which to expand their numbers.
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